|
Back to Home » September 2018 News » Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis |
Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis |
September 15, 2018
TARRYTOWN, N.Y. and PARIS, Sept. 15, 2018 /PRNewswire/ -- Results on skin clearing, itch and certain quality of life measurements were presented today as a late-breaking oral presentation at the 27th EADV Congress Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented...
Source URL: https://www.prnewswire.com:443/news-releases/positive-phase-3-results-presented-for-dupixent-dupilumab-show-significant-improvement-on-multiple-measures-of-disease-severity-in-adolescents-with-moderate-to-severe-atopic-dermatitis-300713187.html
|
|
|
|
